Systemic Lupus Erythematosus
📧 Sign up to get email alerts when something new happens for Systemic Lupus Erythematosus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-10Clinical Trial Results: Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) [Phase 2]
Phase 2 trial results for MK-6194 in adults with systemic lupus erythematosus were terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2026-07-08Clinical Trial Results: Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain [NA]
Completed clinical trial investigating cholinergic anti-inflammatory pathway to treat systemic lupus erythematosus–related musculoskeletal p…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) [Phase 3]
Phase 3 trial evaluating ianalumab added to standard-of-care in systemic lupus erythematosus (SIRIUS-SLE 2) is active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) [Phase 3]
Phase 3 trial update evaluating two regimens of ianalumab on top of standard therapy in systemic lupus erythematosus (SIRIUS-SLE 1).
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus [Phase 3]
Phase 3 trial update investigating adverse events and disease activity changes with oral upadacitinib in adults with moderate to severe syst…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease [Phase 3]
Phase 3 study of enpatoran in participants with cutaneous lupus manifestations with or without systemic lupus erythematosus is currently rec…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) [Phase 3]
Phase 3 clinical trial of enpatoran in participants with cutaneous manifestations of lupus (with or without systemic disease) is currently r…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus [Phase 2]
Phase 2 clinical trial evaluating memantine for cognitive impairment in patients with systemic lupus erythematosus has been completed.
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus
A completed trial compares anifrolumab to real-world standard of care in adults with active systemic lupus erythematosus, focusing on long-t…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus [Phase 1]
This clinical trial update reports a Phase 1 study of NKX019, a CD19 CAR-NK cell therapy, for Systemic Lupus Erythematosus, which has been s…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases [Phase 1]
Phase 1 clinical trial update on HN2302 assessing safety and preliminary efficacy in autoimmune diseases, including systemic lupus erythemat…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA [Phase 1]
A Phase 1a/b tolerability update on the investigational drug NTR-1011 in healthy adults and patients with systemic lupus erythematosus or rh…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics [Phase 1]
First-in-human Phase 1 study of ISH0613 to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects and indiv…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus [Phase 1, Phase 2]
This clinical trial update describes SELECT-SLE, a Phase 1/2 study of biomarker-guided CAR-T target selection for refractory systemic lupus …
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus [Phase 2]
This document reports an active Phase 2 placebo-controlled trial evaluating ESK-001 for active systemic lupus erythematosus.
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
An update from an AstraZeneca-sponsored trial in systemic lupus erythematosus notes achievement of LLDAS5 with anifrolumab. The study is cur…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: PRV-3279-2a Trial in Systemic Lupus [Phase 2]
Provention Bio's PRV-3279-2a Phase 2 trial for systemic lupus erythematosus was terminated, with results posted on 2026-04-03.
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 [Phase 4]
Phase 4 clinical trial update indicating that deucravacitinib is being studied in participants with systemic lupus erythematosus (SLE) or di…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: Respiratory Function, Physical Activity and Fatigue in SLE
This clinical trial update reports the completion of a study evaluating respiratory function, physical activity, and fatigue in people with …
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. [Phase 1]
This Phase 1 trial reports safety data for PiggyBac transposon–based CD-19 CAR T-cells in patients with refractory systemic lupus erythemato…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus [Phase 1, Phase 2]
This is an open-label Phase 1/2 trial to evaluate the safety, efficacy, and cellular kinetics of YTB323 in adults with severe, refractory sy…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). [Phase 1]
Phase 1 ascending-dose study of PIT565 in participants with systemic lupus erythematosus is currently recruiting to assess safety and tolera…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus [Phase 2]
This Phase 2 long-term safety and efficacy study of deucravacitinib in systemic lupus erythematosus has completed data collection and posted…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry
This clinical trial update reports on the safety and effectiveness of BENLYSTA (belimumab) in a systemic lupus erythematosus registry, with …
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus [Phase 2]
Phase 2 clinical trial evaluating SHR-2173 in participants with systemic lupus erythematosus; the study status is not yet recruiting.